文献速递泌尿生殖与妇科肿瘤放疗

单次分割剂量增加提高前列腺癌根治性HDR近距离治疗后良性PSA反弹概率

Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-01-16

研究纳入1999–2014年554例低/中危前列腺癌接受根治性HDR近距离治疗单药治疗且后续PSA检测≥3次的患者,比较四种分割方案(950 cGy×4次、1200 cGy×2次、1350 cGy×2次、1900 cGy×1次)与四种PSA反弹定义下的反弹发生率。中位随访3.7年,全队列3年PSA反弹率随定义阈值升高而降低;单次1900 cGy组PSA反弹>0.2 ng/mL的3年率最高(59.1%),且超过Phoenix生化失败定义(nadir+2 ng/mL)的反弹率也更高。

要点

  • 单次1900 cGy组PSA反弹>0.2 ng/mL的3年率为59.1%,高于其他分割组(P=.002)。
  • 单次1900 cGy相比多分次治疗,PSA反弹>0.2 ng/mL的风险比为1.786(P=.024)。
  • 单次1900 cGy组超过Phoenix生化失败定义(nadir+2 ng/mL)的3年反弹率更高(P=.025)。

核心结论

  • PSA反弹发生率随HDR单次分割剂量增加而升高。
  • 了解治疗后PSA动力学有助于对潜在生化失败的管理决策。

研究设计与样本

  • 回顾性分析1999–2014年554例低或中危前列腺癌接受根治性HDR近距离治疗单药治疗且后续PSA检测≥3次的患者。
  • 采用四种分割方案:950 cGy×4次、1200 cGy×2次、1350 cGy×2次、1900 cGy×1次。
  • 应用四种PSA反弹定义:较前次最低值升高≥0.2、≥0.5、≥1.0、≥2.0 ng/mL并随后回落至最低值。

主要发现

  • 中位随访3.7年,全队列3年PSA反弹率分别为41.3%(nadir+0.2)、28.4%(nadir+0.5)、17.4%(nadir+1.0)、6.8%(nadir+2.0 ng/mL)。
  • PSA反弹>0.2 ng/mL的3年率在950、1200、1350、1900 cGy/分次组分别为42.2%、32.1%、41.0%、59.1%(P=.002)。
  • 单次1900 cGy组相比多分次治疗,PSA反弹>0.2 ng/mL的风险比为1.786(P=.024)。
  • 单次1900 cGy组超过Phoenix生化失败定义(nadir+2 ng/mL)的1、2、3年反弹率分别为4.5%、18.7%、18.7%,高于其他剂量水平(P=.025)。

关键数值与推荐

  • PSA反弹定义:较前次最低值升高≥0.2、≥0.5、≥1.0、≥2.0 ng/mL并随后回落至最低值。
  • Phoenix生化失败定义:nadir+2 ng/mL。

临床怎么用

  • 单次大分割HDR近距离治疗后PSA反弹概率较高,解读PSA升高时需考虑此良性现象以避免过早判定生化失败。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Prostate-specific antigen (PSA) bounce is a temporary elevation of the PSA level above a prior nadir. The purpose of this study was to determine whether the frequency of a PSA bounce following high-dose-rate (HDR) interstitial brachytherapy for the treatment of prostate cancer is associated with individual treatment fraction size. METHODS AND MATERIALS: Between 1999 and 2014, 554 patients underwent treatment of low- or intermediate-risk prostate cancer with definitive HDR brachytherapy as monotherapy and had ≥3 subsequent PSA measurements. Four different fraction sizes were used: 950 cGy × 4 fractions, 1200 cGy × 2 fractions, 1350 cGy × 2 fractions, 1900 cGy × 1 fraction. Four definitions of PSA bounce were applied: ≥0.2, ≥0.5, ≥1.0, and ≥2.0 ng/mL above the prior nadir with a subsequent return to the nadir. RESULTS: The median follow-up period was 3.7 years. The actuarial 3-year rate of PSA bounce for the entire cohort was 41.3%, 28.4%, 17.4%, and 6.8% for nadir +0.2, +0.5, +1.0, and +2.0 ng/mL, respectively. The 3-year rate of PSA bounce >0.2 ng/mL was 42.2%, 32.1%, 41.0%, and 59.1% for the 950-, 1200-, 1350-, and 1900-cGy/fraction levels, respectively (P=.002). The hazard ratio for bounce >0.2 ng/mL for patients receiving a single fraction of 1900 cGy compared with those receiving treatment in multiple fractions was 1.786 (P=.024). For patients treated with a single 1900-cGy fraction, the 1-, 2-, and 3-year rates of PSA bounce exceeding the Phoenix biochemical failure definition (nadir +2 ng/mL) were 4.5%, 18.7%, and 18.7%, respectively, higher than the rates for all other administered dose levels (P=.025). CONCLUSIONS: The incidence of PSA bounce increases with single-fraction HDR treatment. Knowledge of posttreatment PSA kinetics may aid in decision making regarding management of potential biochemical failures.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Hauck CR, Ye H, Chen PY, et al. Increasing Fractional Doses Increases the Probability of Benign PSA Bounce in Patients Undergoing Definitive HDR Brachytherapy for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28586946. doi:10.1016/j.ijrobp.2017.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。